Stocktoria
NEUROONE MEDICAL TECHNOLOGIES Corp NMTC
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2012-11-09
NEUROONE MEDICAL TECHNOLOGIES Corp financials (annual)
Bars are annual figures from 2014 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $3.5M | $2.0M | $171,169 | $178,146 | — | — | $0 | $0 | $773 |
| Gross profit | $5.1M | $1.1M | $456,517 | -$70,794 | -$97,749 | — | — | — | — | — |
| R&D expense | $5.0M | $5.1M | $6.9M | $4.9M | $3.9M | $2.1M | $1.5M | — | — | — |
| SG&A expense | $7.4M | $7.9M | $6.9M | $7.0M | $6.3M | — | — | — | — | — |
| Operating income | -$4.2M | -$11.9M | -$12.0M | -$10.0M | -$10.2M | -$4.9M | -$5.8M | -$32,611 | -$30,915 | -$35,914 |
| Interest expense | — | — | — | — | $3,053 | — | — | — | $14,018 | $330 |
| Income tax | — | — | — | — | -$271,122 | — | — | $0 | $0 | $0 |
| Net income | -$3.6M | -$12.3M | -$11.9M | -$10.0M | -$9.9M | -$13.6M | -$6.8M | -$47,775 | -$62,863 | -$36,244 |
| EPS (diluted) | $-0.09 | $-0.46 | $-0.65 | $-0.63 | $-0.93 | — | — | — | — | — |
| Operating cash flow | -$2.8M | -$11.0M | -$12.9M | -$7.5M | -$8.6M | -$3.4M | -$5.4M | -$21,106 | -$30,229 | -$26,173 |
| Free cash flow | -$2.9M | -$11.1M | -$13.3M | -$7.8M | -$8.7M | -$3.5M | -$5.5M | — | — | — |
| Cash & equivalents | $6.6M | $1.5M | $5.3M | $8.2M | $6.9M | $4.0M | $260,749 | — | — | — |
| Inventory | $2.2M | $2.6M | $1.7M | $704,538 | $98,287 | — | — | — | — | — |
| Total assets | $10.8M | $5.4M | $8.1M | $12.8M | $7.9M | $4.8M | $532,615 | $756,930 | $1,838 | $205 |
| Total liabilities | $3.7M | $4.5M | $1.8M | $3.2M | $1.4M | $2.7M | $1.8M | $1.0M | $83,330 | $35,594 |
| Shareholders' equity | $7.1M | $822,013 | $6.2M | $9.6M | $6.6M | $2.1M | -$1.2M | -$266,220 | -$81,492 | -$35,389 |
Growth · year-over-year · Revenue CAGR 281.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +163.5% | +76.9% | +1040.7% | -3.9% | — | — | — | — | -100.0% | -92.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.